miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.

by Guinn, Daphne, Ruppert, Amy S., Maddocks, Kami, Jaglowski, Samantha, Gordon, Amber, Lin, Thomas S., Larson, Richard, Marcucci, Guido, Hertlein, Erin, Woyach, Jennifer, Johnson, Amy J., Byrd, John C.
Published 2014

Impact of Targeted Therapy on Outcome of Chronic Lymphocytic Leukemia Patients with Relapsed Del(17p13.1) Karyotype at a Single Center

by Stephens, Deborah M., Ruppert, Amy S., Jones, Jeffrey, Woyach, Jennifer, Maddocks, Kami, Jaglowski, Samantha, Andritsos, Leslie A., Flynn, Joseph M., Grever, Michael R., Lozanski, Gerard, Johnson, Amy J., Muthusamy, Natarajan, Heerema, Nyla A., Byrd, John C.
Published 2014

Dinaciclib is a Novel Cyclin Dependent Kinase Inhibitor with Significant Clinical Activity in Relapsed and Refractory Chronic Lymphocytic Leukemia

by Flynn, Joseph, Jones, Jeffrey, Johnson, Amy J., Andritsos, Leslie, Maddocks, Kami, Jaglowski, Samantha, Hessler, Joshua, Grever, Michael R., Ellie, Im, Zhou, Honghong, Zhu, Yali, Zhang, Da, Small, Karen, Bannerji, Rajat, Byrd, John C.
Published 2015

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for 30-Day Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma

by Jaglowski, Samantha M., Ruppert, Amy S., Hofmeister, Craig C., Elder, Patrick, Blum, William, Klisovic, Rebecca, Vasu, Sumithira, Penza, Sam, Efebera, Yvonne A, Benson, Don M., Devine, Steven M., Andritsos, Leslie A
Published 2014